Respiratory Infection Testing: Rapid, Comprehensive, and Cost-Effective

When facing symptoms like coughing, sneezing, or difficulty breathing, swift and accurate diagnosis is non-negotiable. Our Rapid Respiratory Infection Test is the advanced diagnostic solution trusted globally, with over 110,000,000 tests sold worldwide.

Leveraging the reliable Colloidal Gold Chromatographic Immunoassay, this single test delivers results within 12–15 minutes, offering a truly Rapid & Effective diagnostic pathway for clinicians and patients.

Comprehensive Coverage: 1–13 Different Pathogens

Our panel is designed for Up to 95% Clinical Coverage, enabling precise differentiation between common viruses and treatable bacteria. Accurate diagnosis helps Reduce 36–40% Unnecessary Antibiotics.

The 13-Pathogen Panel Includes:

• 8 Viruses: COVID-19, Influenza A, Influenza B, Respiratory Syncytial Virus, Adenovirus, Rhinovirus, Human Metapneumovirus, and Parainfluenza Virus.

• 4 Bacteria: Streptococcus pneumoniae, Legionella pneumophila, Staphylococcus aureus, and Klebsiella pneumoniae.

• 1 Atypical Bacterium: Mycoplasma pneumoniae.

  
  

Unmatched Performance and Value:

Choose our advanced solution to achieve faster turnaround times, greater clinical coverage, and substantial cost savings.

Data References

Unnecessary Antibiotics Reduction (36–40%): A review published in the European Respiratory Review supports the role of rapid pathogen identification in reducing empirical treatment and promoting antimicrobial stewardship. (Source: https://publications.ersnet.org/content/errev/31/166/220051#s2)

Pathogen Coverage and Clinical Needs: The focus on comprehensive viral and bacterial targets aligns with findings on multiplex respiratory panels published in Nature Communications. (Source: https://www.nature.com/articles/s41467-021-25120-6)